Cargando…

Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study

AIMS/HYPOTHESIS: This study aimed to investigate the associations of plasma levels of the pro-inflammatory cytokine high-mobility group box 1 (HMGB1) with incident cardiovascular disease (CVD) and all-cause mortality in patients with type 1 diabetes. METHODS: We prospectively followed 165 individual...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nin, J. W. M., Ferreira, I., Schalkwijk, C. G., Jorsal, A., Prins, M. H., Parving, H.-H., Tarnow, L., Rossing, P., Stehouwer, C. D. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411294/ https://www.ncbi.nlm.nih.gov/pubmed/22752054 http://dx.doi.org/10.1007/s00125-012-2622-1

Ejemplares similares

Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-year follow-up study
por: Nin, Johanna W., et al.
Publicado: (2011)

Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-Year Follow-Up Study
por: Nin, Johanna W.M., et al.
Publicado: (2010)

Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
por: Peeters, S. A., et al.
Publicado: (2017)

Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy
por: Lajer, Maria, et al.
Publicado: (2010)

Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies
por: Peeters, Stijn A., et al.
Publicado: (2017)

Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort
por: Ferreira, Isabel, et al.
Publicado: (2017)

Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes: An Inception Cohort Study
por: Hovind, Peter, et al.
Publicado: (2009)

The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes
por: Dendooven, Amélie, et al.
Publicado: (2011)

Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria
por: Persson, Frederik, et al.
Publicado: (2009)

Vitamin D Levels and Mortality in Type 2 Diabetes
por: Joergensen, Christel, et al.
Publicado: (2010)

A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus
por: Alkhalaf, A., et al.
Publicado: (2010)

Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study
por: Lund, Søren Søgaard, et al.
Publicado: (2008)

Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3‐deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub‐study
por: Piazza, M., et al.
Publicado: (2020)

Osteoprotegerin and Mortality in Type 2 Diabetic Patients
por: Reinhard, Henrik, et al.
Publicado: (2010)

Higher dietary salt intake is associated with microalbuminuria, but not with retinopathy in individuals with type 1 diabetes: the EURODIAB Prospective Complications Study
por: Engelen, Lian, et al.
Publicado: (2014)

Severe Hypoglycemia and Cardiovascular Disease Incidence in Type 1 Diabetes: The EURODIAB Prospective Complications Study
por: Gruden, Gabriella, et al.
Publicado: (2012)

High mobility group box 1: as a 'testament' mediator
por: Maruyama, I, et al.
Publicado: (2005)

Higher High-Mobility Group Box-1 Levels are Associated with White Matter Lesions in Ischemic Stroke Patients
por: Zhao, Jie, et al.
Publicado: (2023)

High Mobility Group Box 1 in Human Cancer
por: Rapoport, Bernardo L., et al.
Publicado: (2020)

Vitamin D Levels, Microvascular Complications, and Mortality in Type 1 Diabetes
por: Joergensen, Christel, et al.
Publicado: (2011)

Tubular and Glomerular Injury in Diabetes and the Impact of ACE Inhibition
por: Nielsen, Stine E., et al.
Publicado: (2009)

High-mobility group box 1: role in ARDS
por: Ishizaka, A, et al.
Publicado: (2005)

High‐Mobility Group Box‐1 and Liver Disease
por: Gaskell, Harriet, et al.
Publicado: (2018)

High mobility group box 1 in diabetic nephropathy
por: Shi, Haitao, et al.
Publicado: (2017)

YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria
por: Rathcke, Camilla Noelle, et al.
Publicado: (2009)

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial
por: Lund, Søren S, et al.
Publicado: (2009)

Serum high-mobility group box-1 protein as a specific marker of severe abdominal injury
por: Sakamoto, Y, et al.
Publicado: (2009)

The Role of High Mobility Group Box 1 in Innate Immunity
por: Lee, Shin-Ae, et al.
Publicado: (2014)

High Mobility Group Box Protein-1 in Wound Repair
por: Ranzato, Elia, et al.
Publicado: (2012)

High-Mobility Group Box 1 in Dry Eye Inflammation
por: Lema, Carolina, et al.
Publicado: (2018)

The Role of High Mobility Group Box 1 in Ischemic Stroke
por: Ye, Yingze, et al.
Publicado: (2019)

Role of High-Mobility Group Box-1 in Liver Pathogenesis
por: Khambu, Bilon, et al.
Publicado: (2019)

High Mobility Group Box 1 Protein in Cerebral Thromboemboli
por: Essig, Fabian, et al.
Publicado: (2021)

Urinary and serum levels of high mobility group box 1
por: Nakamura, Toshihiko, et al.
Publicado: (2023)

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria
por: Zobel, Emilie H., et al.
Publicado: (2017)

Proteolytic inactivation of nuclear alarmin high-mobility group box 1 by complement protease C1s during apoptosis
por: Yeo, J G, et al.
Publicado: (2016)

The role of High Mobility Group Box 1 (HMGB1) in colorectal cancer
por: Süren, Dinç, et al.
Publicado: (2014)

Urinary Liver-Type Fatty Acid-Binding Protein Predicts Progression to Nephropathy in Type 1 Diabetic Patients
por: Nielsen, Stine Elkjaer, et al.
Publicado: (2010)

Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study
por: Peeters, Stijn A, et al.
Publicado: (2015)

Erratum to: Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study
por: Peeters, Stijn A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3a5ssjnmko1kbrv8c10g2as1i7